Evidence map›Paper›PMID 38006674›Full record

Trial reportDrug and alcohol dependence2023

Cocaine abstinence during the "critical period" of a contingency management trial predicts future abstinence in people with cocaine use disorder.

Sean D Regnier, Thomas P Shellenberg, Mikhail N Koffarnus, David H Cox, Joshua A Lile, Craig R Rush, William W Stoops

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sean D RegnierDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA.
Thomas P ShellenbergDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA; Department of Psychology, University of Kentucky College of Arts and Sciences, 171. Funkhouser Drive, Lexington, KY 40506-0044, USA.
Mikhail N KoffarnusDepartment of Family & Community Medicine, University of Kentucky College of Medicine, 2195 Harrodsburg Road, Lexington, KY 40504, USA.
David H CoxDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA.
Joshua A LileDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA; Department of Psychiatry, University of Kentucky College of Medicine, 245 Fountain Court, Lexington, KY 40509-1810, USA; Department of Psychology, University of Kentucky College of Arts and Sciences, 171. Funkhouser Drive, Lexington, KY 40506-0044, USA.
Craig R RushDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA; Department of Psychiatry, University of Kentucky College of Medicine, 245 Fountain Court, Lexington, KY 40509-1810, USA; Department of Psychology, University of Kentucky College of Arts and Sciences, 171. Funkhouser Drive, Lexington, KY 40506-0044, USA.
William W StoopsDepartment of Behavioral Science, University of Kentucky College of Medicine, Medical Behavioral Science Building, 1100 Veterans Drive, Lexington, KY 40536-0086, USA; Department of Psychiatry, University of Kentucky College of Medicine, 245 Fountain Court, Lexington, KY 40509-1810, USA; Department of Psychology, University of Kentucky College of Arts and Sciences, 171. Funkhouser Drive, Lexington, KY 40506-0044, USA; Center on Drug and Alcohol Research, University of Kentucky College of Medicine, 845 Angliana Ave, Lexington, KY 40508, USA. Electronic address: William.stoops@uky.edu.
University of Kentucky · US

Funding

Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
NRSA Training CoreTL1TR001997 · NCATS · UNIVERSITY OF KENTUCKY · PI PENDERGAST, JULIE S, STOOPS, WILLIAM WALTON · 2016 to 2025
$4.2M
A Translational Determination of the Mechanisms of Maladaptive Choice in Opioid Use DisorderR01DA047368 · NIDA · UNIVERSITY OF KENTUCKY · PI BECKMANN, JOSHUA, LILE, JOSHUA ANTHONY · 2019 to 2023
$3.1M
A translational determination of the mechanisms of maladaptive choice in cocaine use disorderR01DA045023 · NIDA · UNIVERSITY OF KENTUCKY · PI BECKMANN, JOSHUA, LILE, JOSHUA ANTHONY · 2018 to 2022
$3.0M
Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine UseR01DA043938 · NIDA · UNIVERSITY OF KENTUCKY · PI STOOPS, WILLIAM WALTON · 2017 to 2022
$2.9M
NCATS NIH HHS TL1 TR001997NIDA NIH HHS R01 DA043938NIDA NIH HHS R01 DA045023NIDA NIH HHS R01 DA047368NIDA NIH HHS T32 DA035200
6 · The paper itself

Abstract

backgroundContingency Management (CM) is being piloted as a treatment for stimulant use disorder in several US states, highlighting the need for treatment optimization. One important goal of optimization is decreasing drug use during the early stages of treatment, which has predicted success in other interventions. However, this "critical period" has not been reported in CM trials. The purpose of this analysis was to determine if, after accounting for baseline abstinence and incentive condition, abstinence in a CM trial for people with Cocaine Use Disorder (CUD) could be predicted by cocaine use during a first-week critical period.

methodsEighty-seven participants with CUD were randomized to receive contingent high or low value incentives for cocaine abstinence or were in a non-contingent control group. Generalized estimating equations (GEE) were used to analyze urine test results over 36 timepoints during the 12-week intervention. To assess for a critical period, the first three visits were included in the GEE as a covariate for remaining urine test results.

resultsParticipants who provided more negative samples during the critical period were significantly more likely to produce a negative urine sample during the remainder of the trial, though some effects of group remained after controlling for the critical period.

conclusionsThese results indicate that a critical period exists for CM trials, and it can explain a substantial amount of future performance. Early contact with an abstinence-contingent high magnitude alternative reinforcer may explain additional performance beyond the critical period, further justifying the use of high magnitude alternative reinforcers.

Indexed as

CocaineCocaine-Related DisordersSubstance-Related DisordersBehavior TherapyHumansMotivationTreatment OutcomeCocaineCocaineContingency ManagementCritical PeriodOptimization

Identifiers

PMID38006674
PMCPMC10841665
OpenAlexW4388793744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.